TTUHSC School of Pharmacy
HomeSOPResearch

Office of Sciences

Office of Sciences Banner

Mission 

The Mission of the Office of Sciences at the TTUHSC School of Pharmacy is to coordinate the school's research needs with our state-of-the-art scientific and technical support and to promote and accelerate research grant applications and new award set-up. 

 
 
Office of Sciences
TTUHSC School of Pharmacy
1406 S. Coulter St.
Amarillo, Texas 79106
Telephone: (806) 414-9328
 
School of Pharmacy Faculty Contacts 

About Us

The Office of Sciences is available to all faculty on each of the four TTUHSC School of Pharmacy campus sites: Amarillo, Abilene, Dallas/Fort Worth and Lubbock. Our purpose is to act as a resource for the granting process, facilitate research and administer internal research programs.

Programs and Services

The Office of Sciences provides and oversees the following programs and services:

Faculty Honors & Achievements

 Featured Grants - Fall 2015

  • Abbruscato Dr. Thomas Abbruscato has been appointed as chairperson of the Drug Discovery for the Nervous System Study Section, Center for Scientific Review, NIH, for the term beginning summer 2015 and ending in summer 2016.
  • Dr. Cucullo Dr. Luca Cucullo was awarded with the President’s young investigator award on November 5, 2015.He was an invited speaker for the University of Rochester-Rochester, NY on October 6, 2015.  The seminar title was “In Vitro Models in Blood-Brain Barrier Research:Current & Novel Technologies”
  • Dr. W. Wang Dr. Wei Wang was invited to give a presentation at the Global Summit on Genitourinary Malignancies on October 22-25, 2015 in Banff, Alberta, Canada. The topic was “HDM2 inhibitors and loss of p53 function
  • Dr. Mikelis Dr. Constantinos Mikelis was invited to lecture at Univeristy of Patras in Rion, Greece in June 2015. He also was an invited speaker at the TTUHSC Abilene Campus.
  • Dr. Srivastava Dr. Sanjay K. Srivastava delivered a keynote speech at the International Conference on Natural Products for Cancer Prevention and Therapy in Istanbul, Turkey. He also deliver a plenary talk at the International Symposium on “Recent trends in Advanced Cancer Prevention” in Seoul, South Korea.
  • Dr. Seifert Dr. Charles Seifert received the Adult Medicine PRN Outstanding Paper Award for 2015 from the American College of Clinical Pharmacy.
  • Dr.Trippier Dr. Trippier was invited to speak at the joint Southwest and Southeast American Chemical Society Regional Meeting in Memphis,TN in the 'Natural Products: Tomorrows Therapeutics' Session.

Dr. Markiewski

Dr. Maciej Markiewski - NIH R01 - Targeting the Premetastatic Niche by Antiangiogenic Immunotherapy


Dr. Magdalena Karbowniczek – DOD Office of Congressionally Directed Medical Research Programs (DOD CDMRP) - identifying mechanisms Initiating LAM and Angiomyolipoma In Tuberous Sclerosis Complex

Dr. Wei Wang – American Cancer Society - Targeting MDM2 Oncogene To Treat Breast Cancer

Dr. Ninh La-Beck – NIH National Cancer Institute (R15) -
Abrogating Nanoparticle-Induced Immunosuppression in Tumor Microenvironment

New Grants and Awards - Fall 2015

Dr. Paul Trippier - Texas Alzheimer’s Research and Care Consortium

Dr. Xinli Liu – CPRIT High Impact / High Risk Research Grant

 Dr. James Stoll – Laura Bush Institute for Women’s Health Centralized Seed Grant Program

Dr. Xinli Liu - Laura W. Bush Women’s Health Institute Seed Grant

 

 YLOP

High Impact Publications

Oncogene

 

Dr. Magdalena Karbowniczek, Associate Professor in the Department of Immunotheapeutics and Biotechnology in Abilene, and her team’s recent publication, “Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex." Dr. Karbowniczek’s laboratory studies the cellular and molecular mechanisms behind a rare disease tuberous sclerosis complex (TSC), which is caused by the inactivating mutations in tumor suppressor genes TSC1 and TSC2. The manuscript is scheduled for publication this year in the cancer journal Oncogene. (Impact Factor 8.459)... READ ARTICLE

Can also be found in BioQuick News

 


Nature Dr. Wei Wang, Research Assistant Professor and Dr. Ruiwen Zhang, Professor, and their team identified a new anticancer agent that targets the cancer-causing gene MDM2, which is linked to poor response to treatment in breast cancer patients. The study, The Pyrido indole MDM2 Inhibitor SP-141 Exerts Potent Therapeutic Effects in Breast Cancer Models, indicates that SP-141 is a novel targeted therapeutic agent that may especially benefit patients with advanced breast cancer. The article was accepted for publishing in the journal, Nature Communications(Impact Factor 10.742)... READ ARTICLE

News Coverage - KGDA - AM News Channel 10

News Coverage - FOX 14

 

Download Free Adobe Reader Get Adobe Reader Adobe Acrobat Reader is required to view items marked with this icon:
Please click on the left image to download the free version.


Content updated on 12/1/15

©